Sanara MedTech

SMTI

Market cap $176M

ICON trades at a low double digit multiple of free cash flow, a fraction of its historical average and a price that materially underestimates the strength of their business. Growth and tumult in private credit, data center financing, and AI driven financial engineering products reinforce the necessity of S&P Global's services. Sanara Medtech continues to be an extremely favorable risk reward with increasing evidence of their product's efficacy recently released and a focus on increasing per hospital doctor penetration.

FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open.

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sanara MedTech, Inc. , (“ Sanara " or the "Company") ( NASDAQ : SMTI ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript

Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago.

FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary ( 1 ) Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024.

Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone

FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 before the U.S. financial markets open. The Company will host a conference call and webcast on March 24, 2026 at 8:00 a.m.

FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time.

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.